Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04455620
Recruitment Status : Not yet recruiting
First Posted : July 2, 2020
Last Update Posted : July 2, 2020
Sponsor:
Information provided by (Responsible Party):
BioNTech SE ( BioNTech RNA Pharmaceuticals GmbH )

Brief Summary:

This is an open-label, multicenter Phase I/IIa dose escalation, safety, pharmacokinetic (PK) and pharmacodynamic (PD) trial of BNT151 with expansion cohorts in various solid tumor indications. The trial consists of Part 1, Part 2A and Part 2B with adaptive design elements:

The monotherapy dose escalation (Part 1) of this clinical trial will enroll patients with various solid tumors that are metastatic (Stage IV) or unresectable for whom there is no available standard therapy likely to confer clinical benefit, or patients who are not candidates for such available therapy. During combination dose escalation (Part 2A), patients of different specific solid tumors (one cohort per indication) will be enrolled and treated with a combination of BNT151 and the respective standard of care (SoC) treatment.

Part 2B is the expansion phase where a predefined number of patients in each indication cohort will be treated with the confirmed recommended phase II dose (RP2D) of BNT151 in combination with respective SoC.


Condition or disease Intervention/treatment Phase
Solid Tumor Biological: BNT151 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 54 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
Estimated Study Start Date : November 2020
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : January 2025

Arm Intervention/treatment
Experimental: Part 1: BNT151
Monotherapy dose escalation in patients with advanced solid malignancies until the maximum tolerated dose (MTD) and/or RP2D
Biological: BNT151
intravenous




Primary Outcome Measures :
  1. Occurrence of dose limiting toxicities (DLTs) within a patient during the DLT evaluation period. [ Time Frame: up to 21 days ]
  2. Occurrence of treatment emergent adverse event (TEAE) within a patient including Grade ≥3, serious, fatal TEAE by relationship. [ Time Frame: through study completion, an average of 6 months ]
    The intensity of an TEAE will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v.5.0).

  3. Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) within a patient due to TEAE. [ Time Frame: through treatment completion, an average of 4 months ]

Secondary Outcome Measures :
  1. Overall response rate (ORR) is defined as the proportion of patients in whom a complete response (CR) or partial response (PR) (per Response Evaluation Criteria in Solid Tumors [RECIST 1.1]) is observed as best overall response. [ Time Frame: through study completion, an average of 6 months ]
  2. Disease control rate (DCR) is defined as the proportion of patients in whom a CR or PR or stable disease (SD) (per RECIST 1.1, SD assessed at least 6 weeks after first dose) is observed as best overall response. [ Time Frame: through study completion, an average of 6 months ]
  3. Duration of response (DOR) is defined as the time from first overall response (CR or PR per RECIST 1.1) to first occurrence of objective tumor progression (Progressive disease (PD) per RECIST 1.1) or death from any cause, whichever occurs first. [ Time Frame: through study completion, an average of 6 months ]
  4. Time to progression (TPP) is defined as the time from first dose of IMP to objective tumor progression (PD per RECIST 1.1). [ Time Frame: through study completion, an average of 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological documentation of the original primary tumor via a pathology report.
  • Measurable disease per RECIST1.1.

For Part 1:

  • Histologically confirmed solid tumor that is metastatic (Stage IV) or unresectable and for whom there is no available standard therapy likely to confer clinical benefit, or patient who is not a candidate for such available therapy. If there is no contraindication, patients should have exhausted all SoC therapies before entering the trial.

For all Parts:

  • ≥18 years of age.
  • Must sign an informed consent form (ICF) indicating that he or she understands the purpose and procedures required for the trial and are willing to participate in the trial prior to any trial-related assessments or procedures.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • Adequate coagulation function at screening as required by the protocol.
  • Adequate hematologic function at screening as required by the protocol.
  • Adequate hepatic function at screening as required by the protocol.
  • Adequate renal function at screening as required by the protocol.
  • Able and willing to attend trial visits as required by the protocol.
  • Women of childbearing potential (WOCBP) must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) test/value at screening. Patients who are postmenopausal or permanently sterilized can be considered as not having reproductive potential.
  • WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire trial, until 6 months after last BNT151 treatment.
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control, e.g. either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the trial and for 6 months after receiving the last dose of BNT151.

Exclusion Criteria:

  • Use of any investigational medical product or device within 28 days before administration of first dose of trial treatment.
  • Has been receiving: radiotherapy, chemotherapy, or molecularly-targeted agents or tyrosine kinase inhibitors within 2 weeks or 5 half-lives (whichever is longer) of the start of trial treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of trial treatment; any live vaccine within 4 weeks of the start of trial treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of trial treatment.
  • Ongoing participation in the active treatment phase of interventional clinical trial.
  • Receives concurrent systemic (oral or IV) steroid therapy >10 mg prednisone daily or its equivalent for an underlying condition.
  • Has had major surgery within the 4 weeks before the first dose of BNT151.
  • Ongoing or active infection requiring IV treatment with anti-infective therapy that has been administered less than 2 weeks prior to the first dose of BNT151.
  • Has ongoing side effects to any prior therapy or procedures for any medical condition not recovered to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 Grade ≤1.

Medical conditions:

  • Current evidence of new or growing brain or leptomeningeal metastases during screening. Patients with known brain metastases may be eligible if they:

    • had radiotherapy, surgery or stereotactic surgery for the brain metastases;
    • have no neurological symptoms (excluding Grade ≤2 neuropathy);
    • have stable brain metastasis on the computed tomography (CT) or magnetic resonance imaging (MRI) scan within 4 weeks before signing the informed consent;
    • are not undergoing acute corticosteroid therapy or steroid taper.
  • Has a history of a cerebrovascular accident or transient ischemic attack less than 6 months ago.
  • Effusions (pleural, pericardial, or ascites) requiring drainage.
  • History of autoimmune disease active or past including but not limited to inflammatory bowel disease, systemic lupus erythematosus (SLE), ankylosing spondylitis, scleroderma, or multiple sclerosis. Has any active immunologic disorder requiring immunosuppression with steroids or other immunosuppressive agents (e.g., azathioprine, cyclosporine A) with the exception of patients with isolated vitiligo, resolved childhood asthma or atopic dermatitis, controlled hypoadrenalism or hypopituitarism, and patients with a history of Grave's disease with stable thyroid function. Patients with controlled hyperthyroidism must be negative for thyroglobulin, thyroid peroxidase antibodies, and thyroid stimulating immunoglobulin prior to administration of trial treatment.
  • Known history of seropositivity for human immunodeficiency virus (HIV) with CD4+ T˗cell (CD4+) counts <350 cells/uL and with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections.
  • Known history/positive serology for hepatitis B requiring active antiviral therapy (unless immune due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy). Patients with positive serology must have HBV viral load below the limit of quantification.
  • Active HCV infection; patients who have completed curative antiviral treatment with HCV viral load below the limit of quantification are allowed.
  • Known hypersensitivity to a component of any trial treatment.
  • Any contraindication to the combination therapies as per United States Prescribing Information (USPI) or Summary of Product Characteristics (SmPC) for patients receiving BNT151 in combination with other systemic anticancer agent(s).
  • Another primary malignancy that has not been in remission for at least 2 years, with the exception of those with a negligible risk of metastasis or death (including but not limited to adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ).

Other comorbidities:

  • Abnormal ECGs that are clinically significant, such as Fridericia-corrected QT prolongation >480 ms.
  • In the opinion of the treating investigator, has any concurrent conditions that could pose an undue medical hazard or interfere with the interpretation of the trial results; these conditions include, but are not limited to:

    • Ongoing or active infection requiring antibiotic/antiviral/antifungal therapy
    • Concurrent congestive heart failure (New York Heart Association [NYHA] Functional Classification Class III or IV)
    • Concurrent unstable angina
    • Concurrent cardiac arrhythmia requiring treatment (excluding asymptomatic atrial fibrillation)
    • Acute coronary syndrome within the previous 6 months
    • Pulmonary embolism within the previous 3 months
    • Significant pulmonary disease (shortness of breath at rest or on mild exertion) for example due concurrent severe obstructive pulmonary disease.
  • Cognitive, psychological or psychosocial impediment that would impair the ability of the patient to receive therapy according to the protocol or adversely affect the ability of the patient to comply with the informed consent process, protocol, or protocol-required visits and procedures.
  • Is pregnant or breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04455620


Contacts
Layout table for location contacts
Contact: BioNTech clinical trials patient information +49 6131 9084 ext 1919 patients@biontech.de
Contact: BioNTech clinical trial information desk +49 6131 9084 ext 0 info@biontech.de

Sponsors and Collaborators
BioNTech RNA Pharmaceuticals GmbH
Investigators
Layout table for investigator information
Study Director: BioNTech Responsible Person BioNTech SE
Layout table for additonal information
Responsible Party: BioNTech RNA Pharmaceuticals GmbH
ClinicalTrials.gov Identifier: NCT04455620    
Other Study ID Numbers: BNT151-01
2019-003572-39 ( EudraCT Number )
First Posted: July 2, 2020    Key Record Dates
Last Update Posted: July 2, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms